Breakingviews: M&A lacking Elan (3:01)
Feb 25 - Royalty Pharma's $6.6 bln approach for the biotech is at a scrawny 4 percent premium. Richard Beales and Robert Cyran discuss why the specialist investor may still be the right owner – at the right price. ( Transcript )
Hard-edged reporting, insight and analysis, Reuters TV breaks ground creating informative news and financial videos. Showcasing Reuters’ 3000 award-winning journalists, Reuters TV delivers high-energy investigative journalism with concise explanations. Check it out and let us know what you think.